RecruitingPhase 2NCT05956587
A Study of SI-B003 and BL-B01D1+SI-B003 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma and Other Solid Tumors
Studying Nasopharyngeal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
- Principal Investigator
- Li Zhang, PHDSun Yat-sen University
- Intervention
- BL-B01D1(drug)
- Enrollment
- 121 target
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2024 – 2027
Study locations (16)
- Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China
- Liuzhou People's Hospital, Liuchow, Guangxi, China
- The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
- Henan Cancer Hospital, Zhengzhou, Henan, China
- Union Hospital Tongji Medical College， Huazhong University of Science and Technology, Wuhan, Hubei, China
- Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China
- Hunan Cancer Hospita, Changsha, Hunan, China
- The Second Affiliated Hospital Of Nanchang University, Nanchang, Jiangxi, China
- Linyi Cancer Hospital, Linyi, Shangdong, China
- The First Affiliated Hospital of Xi'an Jiao Tong University, Xi’an, Shanxi, China
- Tianjin Medical University General Hospital, Tianjin, Tianjin Municipality, China
- +1 more locations on ClinicalTrials.gov
Collaborators
Baili-Bio (Chengdu) Pharmaceutical Co., Ltd.
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05956587 on ClinicalTrials.govOther trials for Nasopharyngeal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT06980038Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT07362979Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal CarcinomaSun Yat-sen University
- RECRUITINGNANCT06796270Hypofractionated Radiotherapy for Nasopharyngeal CarcinomaThe Second Affiliated Hospital of Hainan Medical University
- RECRUITINGPHASE2NCT06059261Envafolimab Combined With Chemoradiotherapy and Recombinant Human Endostatin for LA-NPC.Chongqing University Cancer Hospital
- RECRUITINGNCT07376603IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk FeaturesQiaojuan Guo
- RECRUITINGPHASE3NCT07340515Proton vs Photon IMRT in Locally Advanced Nasopharyngeal Carcinoma: A Phase III TrialMan Hu
- RECRUITINGNCT07232680Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon ChemoradiotherapyCheng-En Hsieh
- RECRUITINGPHASE3NCT0732885440.2Gy Versus 49.2Gy Radiotherapy in Low-Risk Target Volume for Chemosensitive Stage II Nasopharyngeal CarcinomaMing-Yuan Chen